Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

Completed · Phase 3

Conditions studied: HIV Infections, Psoriasis

In brief

To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.

Key facts

Study ID

NCT00002143

Run by

Hoffmann-La Roche

People needed

30

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Any nondermatologic medication.
• Patients must have:
• HIV infection.
• Psoriasis involving at least 10 percent of body surface.

Where it is running

• Beth Israel Med Ctr — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.